Alzheimer disease and cerebrovascular pathology: an update
The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Recent epidemiological and clinico-pathologic data suggest overlaps between Alzheimer disease (AD) and cerebrovascular lesions that may magnify the effect of mild AD pathology and promote progression of cognitive decline or even may precede neuronal damage and dementia. Vascular pathology in the aging brain and in AD includes: 1. cerebral amyloid angiopathy (CAA) with an incidence of 82-98% often associated with ApoE epsilon 2 and causing a) cerebral mass hemorrhages (around 70%, mainly in the frontal and parietal lobes), b) multiple or recurrent microhemorrhages (15%), and c) ischemic (micro-)infarcts or lacunes (around 20%). The frequency of these lesions increases with the severity of CAA and shows no correlation with that of senile amyloid plaques. CAA, significantly more frequent in patients with cerebral hemorrhages or infarcts than in aged controls, is an important risk factor for cerebrovascular lesions in AD. 2. Microvascular changes with decreased density and structural abnormalities causing regional metabolic and blood-brain barrier dysfunctions with ensuing neuronal damage. In large autopsy series of demented aged subjects, around 80% show Alzheimer type pathology, 20-40% with additional, often minor vascular lesions, 7-10% "pure" vascular dementia, and 3-5% "mixed" dementia (combination of AD and vascular encephalopathy). AD cases with additional minor cerebrovascular lesions have significantly more frequent histories of hypertension or infarcts than "pure" AD patients. Vascular lesions in AD include cortical microinfarcts, subcortical lacunes, white matter lesions / leukoencephalopathy, small hemorrhages and corticosubcortical infarcts, while in mixed type dementia multiple larger or hemispheral infarcts are more frequent. Small infarcts in AD patients have no essential impact on global cognitive decline which mainly depends on the severity of Alzheimer pathology, but in early stage of AD they may influence and promote the development of dementia. Recent studies showed lower density of plaques and tangles in brains with cerebrovascular lesions, and similar severity of dementia was related to fewer AD lesions in brains with than in those without small vascular lesions. Further studies will help to elucidate the risk factors and impact of cerebrovascular lesions on the development and progression of dementia in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CAA appears in ≈10% to 30% of unselected brain autopsies and 80% to 100% when in the presence of accompanying Alzheimer disease.136”
In the citing paper
“which virtually all individuals with AD and about a third of aged cognitively normal individuals have) [68, 179]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [68]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“of currently used neuropathological diagnostic criteria for AD (Mirra et al., 1991; Braak and Braak, 1991; Hyman, 1998).”
BackgroundMethodMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · cited 2×
“…to many authors, MD should be diagnosed only if there are sufficient vascular and degenerative lesions to make each diagnosis independently (Tomlinson et al., 1970; Boller et al., 1989; Erkinjuntti, 1988; Jellinger et al., 1990; Mirra et al., 1991), while others suggest the diagnosis of AD…”
Background15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338 · cited 2×
“that came to autopsy, but most patients had mixed disease without clear thresholds of pathological features that predicted dementia (Esiri et al., 2001).”
BackgroundChui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201 · cited 2×
“, 1991), while in the ADDTC criteria (Chui et al., 1992), a second cerebrovascular disorder in addition to AD must be shown to”
BackgroundCerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 6×
“…vessels (Claudio, 1996; Farkas et al., 2000) with increase of collagen IV (Kalaria and Pax, 1995) and breakdown of the BBB are considered important factors for disturbances of cerebral metabolism, reduced cerebral blood flow and neural metabolic changes (Shi et al., 2000; Farkas and Luiten, 2001).”
BackgroundInfluentialHofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062 · cited 4×
“Hypertension and hypercholesterinemia, independent of the ApoE genotype have been shown to be risk factors for AD (Hofman et al., 1997; Skoog et al., 1999).”
BackgroundInfluentialClinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Cited by
Items 301–400 of 681
Peters, R., Beckett, N. S., Nunes, M., FLETCHER, A. E., Forette, F. O., & Bulpitt, C. J. (2006) · Drugs & Aging · doi:10.2165/00002512-200623010-00008 · Cited by 38
Peres, R., De Guio, F., Chabriat, H., & Jouvent, E. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15625352 · Cited by 36
Asanad, S., Ross‐Cisneros, F. N., Barrón, E., Nassisi, M., Sultan, W., Karanjia, R., & Sadun, A. A. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.005 · Cited by 50
“Pathological inflammatory cascades have been postulated as the cause of progressive neurodegeneration and vasoregression of the neurovascular choroid [33-35].”
BackgroundHypertension, dementia, and antihypertensive treatment: Implications for the very elderly
Peters, R., & Beckett, N. S. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0047-0 · Cited by 38
“Multiple types of vascular pathology have been associated with AD, including microvascular degeneration, disorders of the blood–brain barrier, white matter lesions, microinfarctions, and cerebral hemorrhages [ 24 ].”
BackgroundMyelin Basic Protein Binds to and Inhibits the Fibrillar Assembly of Aβ42 in Vitro
Hoos, M. D., Ahmed, M., Smith, S. O., & Van Nostrand, W. E. (2009) · Biochemistry · doi:10.1021/bi900037s · Cited by 34
“Cerebral amyloid angiopathy (CAA), a condition prevalently found in AD, is characterized by fibrillar Aβ deposition within and along primarily small and medium-sized arteries and arterioles of the cerebral cortex and leptomeninges and in the cerebral microvasculature (7, 11, 12).”
Xu, F., Fu, Z., Dass, S., Kotarba, A. E., Davis, J., Smith, S. O., & Van Nostrand, W. E. (2016) · Nature Communications · doi:10.1038/ncomms13527 · Cited by 35
Walker, L., Simpson, H., Thomas, A. J., & Attems, J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01714-7 · Cited by 39
“Cerebral amyloid angiopathy (CAA), observed in 20–100% of AD cases [20, 32, 38, 48], is defined by the deposition of Aβ (predominantly Aβ 1-40 ) in the walls of meningeal vessels, cerebral arteries, arterioles, and less commonly in the capillaries and vein vessel walls [28, 49, 67].”
BackgroundBoada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.009 · Cited by 36
Hypertension and Alzheimer’s disease: indirect effects through circle of Willis atherosclerosis
Eglit, G. M. L., Weigand, A. J., Nation, D. A., Bondi, M. W., & Bangen, K. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa114 · Cited by 38
“CAA is present in up to 80% of Alzheimer’s dementia cases (Jellinger, 2002).”
BackgroundMa, Y., Liu, Y., Han, F., Qiu, H., Shi, J., Huang, N., Hou, N., & Sun, X. (2021) · Aging · doi:10.18632/aging.202881 · Cited by 35
“90% of affected patients have cerebral amyloid vascular disease [70], which is characterized by the accumulation”
BackgroundSerum Hepatocyte Growth Factor Is Associated with Small Vessel Disease in Alzheimer’s Dementia
Zhu, Y., Hilal, S., Chai, Y. L., Ikram, M. K., Venketasubramanian, N., Chen, C., & Lai, M. K. P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00008 · Cited by 39
“Several neuroimaging markers of CeVD, such as cortical infarct, lacunes and especially white matter hyperintensities (WMH) are associated with AD and may contribute to disease deterioration (Jellinger, 2002; Moghekar et al., 2012; Toledo et al., 2013; Attems and Jellinger, 2014).”
BackgroundHayden, M. R. (2024) · Biomedicines · doi:10.3390/biomedicines12071463 · Cited by 36
“…in the Religious Orders Study (404 individuals), 84% of participants had CAA [60], and this study also found that CAA frequently co-occurred with LOAD, with an estimated 78–98% of individuals with LOAD also having CAA [61]; however, only ~25% of patients with LOAD also have severe CAA [62].”
BackgroundMilner, E., Zhou, M., Johnson, A. W., Vellimana, A. K., Greenberg, J. K., Holtzman, D. M., Han, B. H., & Zipfel, G. J. (2014) · Stroke · doi:10.1161/strokeaha.114.006078 · Cited by 39
Impact of spontaneous intracerebral hemorrhage on cognitive functioning: An update
Planton, M., Raposo, N., Danet, L., Albucher, J., Péran, P., & Pariente, J. (2017) · Revue Neurologique · doi:10.1016/j.neurol.2017.06.010 · Cited by 41
Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents
Nag, S., Barnes, L. L., Yu, L., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010602 · Cited by 37
“explain the higher frequency of CAA in this group because >90% of AD cases have coexisting CAA.(32) HS was found only in Black decedents with moderate/severe LATE-NC, and the stated frequency of HSmay be an underestimate because only 1 section of the mid hippocampus was analyzed.”
BackgroundChong, J. R., Hilal, S., Ashton, N. J., Karikari, T. K., Reilhac, A., Vrooman, H. A., Schöll, M., Zetterberg, H., Blennow, K., Chen, C., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12396 · Cited by 43
“For brain atrophy, CIND, AD dementia, and VaD subjects had significantly higher MTA scores (median [interquartile range (IQR)] = 1 [1], 2 [2] and 2 [1], respectively) and lower hippocampal volume (mean [standard deviation (SD)] = 6.”
BackgroundZhao, L., Hou, L., Sun, H., Yan, X., Sun, X., Li, J., Bian, Y., Chu, Y., & Liu, Q. (2011) · Molecules · doi:10.3390/molecules16054005 · Cited by 34
“Nowadays, many researches suggest that fibrillar Aβ accumulates at sites in the cerebrovasculature, particularly around arterioles and capillaries of the cerebral cortex and leptomeninges [3,4], resulting in cerebral amyloid angiopathy (CAA).”
BackgroundPlatelets in the Alzheimer’s Disease Brain: do they Play a Role in Cerebral Amyloid Angiopathy?
Kniewallner, K. M., Ehrlich, D., Kiefer, A., Marksteiner, J., & Humpel, C. (2015) · Current Neurovascular Research · doi:10.2174/1567202612666150102124703 · Cited by 33
“Thus, besides their normal function in hemostasis, platelets play a central role in pathological thrombus formation, which is a crucial risk factor for AD development [8, 9].”
Tian, J., Shi, J., Bailey, K. L., Harris, J. M., Pritchard, A. L., Lambert, J., Chartier‐Harlin, M., Pickering-Brown, S. M., Lendon, C. L., & Mann, D. M. A. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.072 · Cited by 34
Burbach, G. J., Vlachos, A., Ghebremedhin, E., Turco, D. D., Coomaraswamy, J., Staufenbiel, M., Jucker, M., & Deller, T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.003 · Cited by 39
Immunotherapy as treatment for Alzheimer’s disease
Hawkes, C. A., & McLaurin, J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1535 · Cited by 35
“6 Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism. Acta Neurol. Scand. 114(1), 38–46 (2006).”
BackgroundApolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice
Ritchie, M., Sajjadi, S. A., & Grill, J. D. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200230 · Cited by 38
Interactions between nanoparticles and pathological changes of vascular in Alzheimer’s disease
Lei, T., Yang, Z., Li, H., Qin, M., & Gao, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115219 · Cited by 36
Cerebral Microbleeds as a Biomarker in Alzheimer’S Disease? A Review in The Field
Shams, S., & Wahlund, L.-O. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.101 · Cited by 32
Zha, Z., Jin, S., Choi, S., Wu, Z., Plöessl, K., Smith, M., & Kung, H. F. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00127 · Cited by 37
Zhu, N., Wei, M., Yuan, L., He, X., Chen, C., Ji, A., & Zhang, G. (2022) · Aging · doi:10.18632/aging.204029 · Cited by 34
Vascular Endothelial Barrier Dysfunction Mediated by Amyloid-β Proteins
Nagababu, E., Usatyuk, P. V., Enika, D., Natarajan, V., & Rifkind, J. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1104 · Cited by 32
“In addition, A β deposits are found in brain capillaries, small arteries, and arterioles producing cerebral amyloid angiopathy (CAA) [31–33] in spite of an anti-amyloidogenic effect of BBB by preferential sequestration of the soluble A β -apoJ complex and excluding pro-amyloidogenic isoforms of…”
Alzheimer’s Disease, Astrocytes and Kynurenines
Dézsi, L., Tuka, B., Martos, D., & Vécsei, L. (2015) · Current Alzheimer Research · doi:10.2174/156720501205150526114000 · Cited by 32
Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy
Remes, A. M., Finnilä, S., Mononen, H., Tuominen, H. J., Takalo, R., Herva, R., & Majamaa, K. (2004) · Neurology · doi:10.1212/01.wnl.0000129988.68657.fa · Cited by 34
Hijazi, Z., Yassi, N., O'Brien, J. T., & Watson, R. (2021) · European Journal of Neurology · doi:10.1111/ene.15211 · Cited by 32
“CAA results from the deposition of βamyloid (Aβ) in the cerebral and meningeal vasculature (mainly arteries and arterioles), with an increasing prevalence with age [32].”
BackgroundSpecific Amyloid β Clearance by a Catalytic Antibody Construct
Planque, S. A., Nishiyama, Y., Sonoda, S., Lin, Y., Taguchi, H., Hara, M., Kolodziej, S. J., Mitsuda, Y., González‐Calle, V., Sait, H. B. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641738 · Cited by 32
“In addition to deposits of A (1– 42) (A 42) that damage the brain parenchyma, accumulation of A (1– 40) (A 40) in blood vessel walls causes microvasculature-related neuroinflammation and compromised blood-brain barrier (BBB) integrity (2), resulting in cerebral amyloid angiopathy (CAA) in nearly all AD patients (3).”
BackgroundConstantinescu, P., Brown, R., Wyatt, A. R., Ranson, M., & Wilson, M. R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786657 · Cited by 34
“Additionally, the concentration of plg in cerebrospinal fluid is further increased during breakdown of the blood– brain barrier (33) that occurs, for example, in Alzheimer’s disease (35, 36).”
Jeynes, B., & Provias, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0099-z · Cited by 34
“and -amyloid senile plaques or neuronal neuroWbrillary tangle formation [29, 36].”
BackgroundPotential Retinal Biomarkers in Alzheimer’s Disease
García-Bermúdez, M. Y., Vohra, R., Freude, K., van Wijngaarden, P., Martin, K. R. G., Thomsen, M. S., Aldana, B. I., & Kolko, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115834 · Cited by 33
“Vascular changes in the brain, including cerebral amyloid angiopathy and blood-brain barrier dysfunction, are known to be associated with AD [257].”
BackgroundBouvy, W. H., van Veluw, S. J., Kuijf, H. J., Zwanenburg, J. J. M., Kappelle, J. L. J., Luijten, P. R., Koek, H. L., Geerlings, M. I., Biessels, G. J., & On behalf of the Utrecht Vascular Cognitive Impairment (VCI) Study Group (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19838087 · Cited by 31
“Alzheimer’s disease (AD).(8,9) Lobar cerebral microbleeds (CMBs), i.”
BackgroundRipp, I., Stadhouders, T., Savio, A. M., Goldhardt, O., Cabello, J., Calhoun, V. D., Riedl, V., Hedderich, D. M., Diehl‐Schmid, J., Grimmer, T., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234930 · Cited by 32
“This finding can be explained by, for instance, a more profound cerebrovascular disease in AD patients, as well by sporadic CAA, which is often associated with AD (49).”
BackgroundEffect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats
Jenkins, T. A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.021 · Cited by 31
Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?
Kokjohn, T. A., Maarouf, C. L., & Roher, A. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2429 · Cited by 30
“Microhemorrhages are frequently observed in AD patients [97], thus implying that the unchecked accumulation of vascular amyloid can itself be intrinsically destructive.”
BackgroundHoos, M. D., Ahmed, M., Smith, S. O., & Nostrand, W. E. V. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m603494200 · Cited by 34
Tarawneh, R. (2023) · Biomolecules · doi:10.3390/biom13050830 · Cited by 29
“Therefore, new vessel formation in AD is ineffective and dysregulated, causing aberrant vessel formation, premature vessel pruning, and reduced microvascular density [194,195].”
BackgroundChen, S., Kang, Z., Hu, X., Hu, B., & Zou, Y. (2007) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.2007.b0242 · Cited by 29
“Recent studies showed lower density of plaques and tangles in brains with cerebrovascular lesions ( Jellinger, 2002 ).”
Depressive symptoms and white matter changes in patients with dementia
Lind, K., Jonsson, M. A. G., Karlsson, I., Sjögren, M. J. C., Wallin, A., & Edman, Å. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1433 · Cited by 31
Erkinjuntti, T., Gauthier, S. G., Bullock, R. M., Kurz, A., Hammond, G., Schwalen, S., Zhu, Y., & Brashear, R. H. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083028 · Cited by 29
ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy
Domingues‐Montanari, S., Hernández‐Guillamón, M., Fernández‐Cadenas, I., Mendióroz, M., Boada, M., Munuera, J., Rovira, À., Maisterra, O., Parés, M., Gutierrez, M., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.01.019 · Cited by 33
“AA is also a common pathological finding in Alzheimer isease (AD) patients with a frequency up to 98% in some utopsy series (Jellinger, 2002).”
BackgroundN-terminal Domain of Myelin Basic Protein Inhibits Amyloid β-Protein Fibril Assembly
Liao, M.-C., Hoos, M. D., Aucoin, D., Ahmed, M., Davis, J., Smith, S. O., & Van Nostrand, W. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.169599 · Cited by 29
Animal models of spontaneous intracerebral hemorrhage
Alharbi, B. M., Tso, M. K., & Macdonald, R. L. (2016) · Neurological Research · doi:10.1080/01616412.2016.1144671 · Cited by 35
Brain type carnosinase in dementia: a pilot study
Balion, C. M., Benson, C. M., Raina, P. S., Παπαϊωάννου, Α., Patterson, C., & Ismaila, A. (2007) · BMC Neurology · doi:10.1186/1471-2377-7-38 · Cited by 32
Pericytes in Alzheimer’s Disease: Novel Clues to Cerebral Amyloid Angiopathy Pathogenesis
Salmina, A. B., Komleva, Y. K., Lopatina, O. L., & Birbrair, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16908-4_7 · Cited by 30
Loftus, J. R., Puri, S., & Meyers, S. P. (2023) · Insights into Imaging · doi:10.1186/s13244-022-01358-6 · Cited by 33
The Blood-Brain Barrier and Microvascular Water Exchange in Alzheimer's Disease
Anderson, V. C., Lenar, D. P., Quinn, J. F., & Rooney, W. D. (2011) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2011/615829 · Cited by 32
Princz-Kranz, F. L., Mueggler, T., Knobloch, M., Nitsch, R. M., & Rudin, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.002 · Cited by 28
“Aβ-CAA affects predominantly small- and medium-sized brain vessels includingmeningeal and cerebral arteries, arterioles, and, less frequently, capillaries and veins of cerebral cortex and subcortical structures (Greenberg, 2002; Greenberg et al., 2004; Jellinger, 2002; Weller et al., 2009).”
BackgroundKniewallner, K. M., Wenzel, D., & Humpel, C. (2016) · Scientific Reports · doi:10.1038/srep28447 · Cited by 27
“CAA is characterized by deposition of A β peptides in the walls of leptomeningeal and parenchymal vessels 31 and therefore a feature of aging and AD.”
Agyare, E. K., Leonard, S. R., Curran, G. L., Yu, C. C., Lowe, V. J., Paravastu, A. K., Poduslo, J. F., & Kandimalla, K. K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300352c · Cited by 27
Human Apolipoprotein E Redistributes Fibrillar Amyloid Deposition in Tg-SwDI Mice
Xu, F., Vitek, M. P., Colton, C. A., Previti, M. L., Gharkholonarehe, N., Davis, J., & Van Nostrand, W. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1042-08.2008 · Cited by 27
Previti, M. L., Zhang, W., & Nostrand, W. E. V. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-18 · Cited by 30
“Additionally, cerebral vascular smooth muscle cells and pericytes, which degenerate in the presence of accumulated amyloid, may directly participate in the inflammatory process contributing to cognitive decline, cerebral vessel wall degeneration, and hemorrhage [ 3-7 ].”
BackgroundInfluentialSyntactic comprehension deficits are associated with MRI white matter alterations in dementia
Giovannetti, T., HOPKINS, M. W., Crawford, J., Bettcher, B. M., Schmidt, K. S., & Libon, D. J. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080715 · Cited by 28
“There is accumulating evidence to suggest that the neuropathology underlying the clinical syndromes of AD and VaD can overlap (Jellinger, 2002; Pantoni & Garcia, 1997; see also Libon et al., 2004, 2008; Price et al., 2005).”
BackgroundResultXu, F., Kotarba, A. E., Ou-Yang, M.-H., Fu, Z., Davis, J., Smith, S. O., & Nostrand, W. E. V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536565 · Cited by 27
“In the case of AD, the accumulation of fibrillar A occurs in two distinct compartments: in the brain parenchyma in the form of plaques and in cerebral blood vessels as vascular amyloid (5, 14, 15).”
BackgroundNa, H., Gan, Q., Mcparland, L., Yang, J. B., Yao, H., Tian, H., Zhang, Z., & Qiu, W. Q. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108017 · Cited by 30
“Since more and more studies have shown that cerebrovasculature may play an important role in AD pathogenesis (Arvanitakis et al., 2016; Jellinger, 2002; Santos et al., 2017), BIBN may reduce AD pathogenesis through affecting cerebrovasculature.”
BackgroundBamji‐Mirza, M., Callaghan, D., Najem, D., Shen, S., Hasim, M. S., Yang, Z., & Zhang, W. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131949 · Cited by 26
“Moreover, we chose A 1-42 peptides because a stronger A stimulus [31] was needed to evoke an inflammatory response in these cells, and A 1-42 may play a greater role in the development of cerebral amyloid pathology than previously thought [32] in addition to A 1-40 deposits that are mainly found in the vasculature [33…”
MethodBlood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice
Abdallah, I. M., Al-Shami, K. M., Yang, E., & Kaddoumi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031231 · Cited by 27
“To clarify these results further, the bjective of this study was t i vestigat the effect of pharmacological disr ption of the BBB on Aβ-related pathology in TgSwDI, a mouse model for CAA and AD.”
BackgroundInfluentialGandy, S., & Walker, L. C. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.08.002 · Cited by 29
Jia, J., Cui, M., Dai, J., & Liu, B. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00209 · Cited by 26
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
“With ApoE ε4 as a main genetic risk factor for AD, the cross-interaction between ApoE and Aβ has a major contribution to the progression of CAA and AD.”
BackgroundInfluentialDecreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia
Smesny, S., Stein, S. H., Willhardt, I., Lasch, J., & Sauer, H. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0081-0 · Cited by 26
“Indeed, shared pathophysiology of AD and VD has been also repeatedly discussed in the literature (Hentschel et al. 2005; Jellinger 2002; Kalaria and Ballard 1999).”
BackgroundMendel, T. A., Wierzba‐Bobrowicz, T., Lewandowska, E., Stępień, T., & Szpak, G. M. (2013) · Polish Journal of Pathology · doi:10.5114/pjp.2013.39334 · Cited by 29
“Although CAA can be detected pathologically for over 80% of patients with a pathologically certain Alzheimer syndrome [25], less than 50% of patients suffering from a pathologically certain CAA present the pathological criteria for the Alzheimer syndrome [17, 26].”
BackgroundAbcg2 deficiency augments oxidative stress and cognitive deficits in Tg‐SwDI transgenic mice
Zeng, Y., Callaghan, D., Xiong, H., Yang, Z., Huang, P., & Zhang, W. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07783.x · Cited by 25
Spontaneous upper limb monoplegia secondary to probable cerebral amyloid angiopathy
Sadek, A., Parmar, N. K., Sadek, N.-H., Jaiganesh, S., Elkhodair, S., & Jaiganesh, T. (2012) · International Journal of Emergency Medicine · doi:10.1186/1865-1380-5-1 · Cited by 24
“Cerebral amyloid angiopathy is not an uncommon pathological finding, especially in the aged brain and in those with Alzheimer’s dementia [4].”
BackgroundInfluentialChatterjee, P., Tegg, M., Pedrini, S., Fagan, A. M., Xiong, C., Singh, A. K., Taddei, K., Gardener, S. L., Masters, C. L., Schofield, P. R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062931 · Cited by 25
“CAA pathology is widely seen in patients with Alzheimer’s disease (AD), of whom around 80% exhibit CAA co-morbidity [3].”
BackgroundRetinal Vascular Physiology Biomarkers in a 5XFAD Mouse Model of Alzheimer’s Disease
Matei, N., Leahy, S., Blair, N. P., Burford, J. L., Rahimi, M., & Shahidi, M. (2022) · Cells · doi:10.3390/cells11152413 · Cited by 24
“Previous literature has reported that CAA, in which plaques are increased in cerebral blood vessels and tissue, was observed in more than 80% of AD patients [47].”
BackgroundAmyloid angiopathy in idiopathic Parkinson's disease. Immunohistochemical and ultrastructural study.
Bertrand, E., Lewandowska, E., Stępień, T., Szpak, G. M., Pasennik, E., & Modzelewska, J. (2008) · PubMed · Cited by 25
H2S- and NO-Signaling Pathways in Alzheimer's Amyloid Vasculopathy: Synergism or Antagonism?
Salmina, A. B., Komleva, Y. K., Szijártó, I. A., Gorina, Y. V., Lopatina, O. L., Gertsog, G. E., Filipović, M. R., & Gollasch, M. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00361 · Cited by 24
“As such, up to 40% of the elderly population without clinical manifestations of AD demonstrate features of cerebral amyloid angiopathy, and up to 80% of people suffering from AD exhibit signs of cerebral amyloid angiopathy (Jellinger, 2002).”
BackgroundResumption of Anticoagulation After Intracranial Hemorrhage
da Silva, I. R. F., & Frontera, J. A. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0477-y · Cited by 24
Neurocognitive disorder in hypertensive patients. Heart–Brain Study
Vicario, A., Cerezo, G. H., Sueldo, M. D., Zilberman, J. M., Pawluk, S. M., Lódolo, N., Cerchio, A. E. D., Ruffa, R. M., Plunkett, R., Giuliano, M. E., et al. (2018) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2018.01.004 · Cited by 27
Grossmann, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081890 · Cited by 26
“However, both events can co-exist at the same time [67].”
BackgroundInfluentialSingh, B., Lavezo, J., Gavito-Higuera, J., Ahmed, F., Narasimhan, S. S., Brar, S. K., Cruz‐Flores, S., & Kraus, J. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220055 · Cited by 27
“8% to 20% of non-traumatic hemorrhages, which makes CAA the second leading cause of spontaneous ICH [4, 6].”
BackgroundInfluentialMicrovascular arterial disease of the brain and the heart: a shared pathogenesis
Bradley, C. P., & Berry, C. (2023) · QJM · doi:10.1093/qjmed/hcad158 · Cited by 25
“25 CSVD is detected using MRI, particularly T2-weighted sequences.”
MethodZekry, D., & Gold, G. (2010) · Drugs & Aging · doi:10.2165/11538250-000000000-00000 · Cited by 26
Delacourte, A., Campion, D., & Davous, P. (2007) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(07)44093-3 · Cited by 24
Becerra-Calixto, A., Posada‐Duque, R., & Cardona‐Gómez, G. P. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0992-1 · Cited by 24
Alzheimer’s disease, brain immune privilege and memory: a hypothesis
Arshavsky, Y. I. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0524-4 · Cited by 25
“…that among the effects the cardiovascular factors leading to AD is the interruption of the BBB (reviewed by Sparks, 1997; Kalaria, 1999, 2003; de la Torre, 2002, 2004; Jellinger, 2002; Iadecola, 2004; Sadowski et al., 2004; Jellinger and Attems, 2005; Szczygielski et al., 2005; Zlokovic, 2005).”
BackgroundInfluentialPatricio-Martínez, A., Patricio, F., Macuil-Chapuli, E., Martínez-Juárez, E. Á., Flores-Díaz, S., Cedillo-Ramirez, M. L., & Limón, I. D. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1598011 · Cited by 28
“A β deposits are primarily located in the hippocampus, neocortex, and cerebral vasculature (Bloom, 2014; Jellinger, 2002; Viswanathan and Greenberg, 2011).”
Metal-dependent amyloid β-degrading catalytic antibody construct
Nishiyama, Y., Taguchi, H., Hara, M., Planque, S. A., Mitsuda, Y., & Paul, S. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.03.026 · Cited by 24
FMRI: Use in Early Alzheimer‘s Disease and in Clinical Trials
Pihlajamaki, M. M., & Sperling, R. A. (2008) · Future Neurology · doi:10.2217/14796708.3.4.409 · Cited by 23
“AD is a neurodegenerative syndrome that typically begins with an insidious impairment of episodic memory function, but can be heterogeneous in terms of genetic background [2], neuropathological and neuroradiological patterns [3–5] as well as response to treatment [6].”
BackgroundPontes‐Neto, O. M., Auriel, E., & Greenberg, S. M. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.134 · Cited by 25
“CAA pathology is common in the elderly, with a prevalence from 10–50 % of the general elderly population, in autopsy series.(34,35) Some CAA pathology is also present in nearly all brains with AD and advanced CAA is present in approximately 25 % of AD brains.”
Resuming anticoagulant therapy after intracerebral bleeding
Becattini, C., Sembolini, A., & Paciaroni, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.05.012 · Cited by 22
Fakan, B., Reisz, Z., Zádori, D., Vécsei, L., Klivènyi, P., & Szalárdy, L. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02174-2 · Cited by 26
“2000) [with which it shows some 70–80% overlap (Jellinger 2002; Brenowitz et al.”
BackgroundCerebral Microbleeds in Fragile X–Associated Tremor/Ataxia Syndrome
Salcedo‐Arellano, M. J., Wang, J. Y., McLennan, Y. A., Doan, M., Cabal‐Herrera, A. M., Jimenez, S., Wolf‐Ochoa, M., Sanchez, D., Juárez, P., Tassone, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28559 · Cited by 25
“The gradual deposit of iron in the process of aging is well known.32-34 Increased levels of iron are present in the substantia nigra in Parkinson’s disease35,36 and in the putamen, caudate, and temporal gray matter (GM) in AD.37-40 The motor and cognitive deficits found in patients with multiple sclerosis (MS) are cor…”
BackgroundInfluentialDiretrizes para o manejo de pacientes com hemorragia intraparenquimatosa cerebral espontânea
Pontes‐Neto, O. M., Filho, J. O., Valiente, R. A., Friedrich, M., Pedreira, B. B., Rodrigues, B., Liberato, B. B., & de Freitas, G. R. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500034 · Cited by 82
Beckmann, N., Doelemeyer, A., Zurbruegg, S., Bigot, K., Theil, D. J., Frieauff, W., Kolly, C., Moulin, P., Neddermann, D., Kreutzer, R., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.009 · Cited by 27
Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy?
Lee, J., & Markus, H. S. (2006) · Neurology · doi:10.1212/01.wnl.0000196863.43951.44 · Cited by 23
Fuchsberger, T., Yuste, R., Martínez‐Bellver, S., Blanco-Gandia, M.-C., Torres-Cuevas, I., Blasco‐Serra, A., Arango, R., Miñarro, J., Rodríguez‐Arias, M., Teruel‐Martí, V., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190274 · Cited by 21
Effects of cerebral amyloid angiopathy on the brain vasculome
Deng, W., Guo, S., van Veluw, S. J., Yu, Z., Chan, S. J., Takase, H., Arai, K., Ning, M., Greenberg, S. M., Lo, E. H., et al. (2022) · Aging Cell · doi:10.1111/acel.13503 · Cited by 23
“The deposition of β- amyloid (Aβ) peptides within cerebral blood vessels is the primary signature of CAA, and this also occurs in 85– 95% of AD patients (Jellinger, 2002; Pfeifer et al., 2002).”
BackgroundCatalytic Antibodies: Design, Expression, and Their Applications in Medicine
Zhao, D., Chen, J., Hu, X., & Zhang, S. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04183-1 · Cited by 24
“A (1–42) (A42) deposits harm brain structures, whereas A A (1–40) (A40) accumulates in vessel walls, causing microvascular-related neuroinflammation and impaired blood–brain barrier (BBB) integrity, which leads to cerebral amyloid angiopathy (CAA) in almost all AD patients [116, 165].”
BackgroundAlzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
Genetic Animal Models of Cerebral Vasculopathies
Lee, J. H., Bacskai, B. J., & Ayata, C. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00002-0 · Cited by 23
Plaschke, K. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0191-2 · Cited by 21
“Later, detailed light and electron microscopic examinations of the cerebral blood vessels disclosed a variety of morphometric and morphological alterations in the microvasculature in various brain regions of aged rats, ageing humans and in patients with dementia (Bell and Ball, 1986; Jellinger, 2002).”
BackgroundJi, X., Li, C., Lu, Y., Chen, Y., & Guo, L. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.053 · Cited by 20
Cerebral amyloid angiopathy – The modified Boston criteria in clinical practice
Caetano, A., Ladeira, F. F., Barbosa, R. P., Calado, S., & Baptista, M. V. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.11.021 · Cited by 23
Banerjee, S., & Poddar, M. K. (2020) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2020.104239 · Cited by 21
Endothelial Cells and the Cerebral Circulation
Lansdell, T. A., Chambers, L. C., & Dorrance, A. M. (2022) · Comprehensive physiology · doi:10.1002/cphy.c210015 · Cited by 22
Metadata
- Authors
- Jellinger, K. A.
- Affiliations
- Ludwig Boltzmann für Klinische Neurobiologie (AT)
- Corresponding author
- Jellinger, K. A.
- ORCID
- Jellinger, K. A.
- Venue
- Journal of Neural Transmission
- Published
- 2002-05-01
- Volume
- 109
- Issue
- 5-6
- Pages
- 813-836
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2084675121
- Cited by
- 680
- References
- 114
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 32 · 2023: 19 · 2022: 38 · 2021: 32 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 22 · 2016: 30 · 2015: 44 · 2014: 38 · 2013: 27 · 2012: 39
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, cerebrovascular pathology, cerebral amyloid angiopathy, cerebral hemorrhage, microinfarcts, lacunes, white matter lesions, mixed dementia, vascular dementia, cognitive decline, dementia progression, blood-brain barrier dysfunction
- MeSH terms
- Alzheimer Disease, Blood Vessels, Cerebrovascular Circulation, Cerebrovascular Disorders, Diagnosis, Differential, Humans, Microcirculation, Risk Factors, Dementia, Vascular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.